Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05465941 · ClinicalTrials.gov registry record · Phase 2
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
A Phase 2 study of Platinum-Resistant Ovarian Carcinoma and Platinum-Resistant Fallopian Tube Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT05465941 is a Phase 2 study of Platinum-Resistant Ovarian Carcinoma and Platinum-Resistant Fallopian Tube Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 43 participants, roughly in line with the 42-participant average among 13 other Platinum-Resistant Ovarian Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT05465941, a Phase 2 study of Platinum-Resistant Ovarian Carcinoma and Platinum-Resistant Fallopian Tube Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests whether pegylated SN-38 conjugate PLX038 (PLX038) works to shrink tumors in patients with ovarian, primary peritoneal, and fallopian tube cancers that has spread from where it first started (primary site) to other places in the body (metastatic). PLX038 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy
- DRUG Pegylated SN-38 Conjugate PLX038
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-09-14 |
| Est. Completion | 2031-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05465941
The ClinicalTrials.gov registry entry for NCT05465941 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 42-participant average among 13 other Platinum-Resistant Ovarian Carcinoma trials with a reported enrollment target. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Platinum-Resistant Ovarian Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT05465941 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05465941 about?
NCT05465941 is a clinical study titled "PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer". This phase II trial tests whether pegylated SN-38 conjugate PLX038 (PLX038) works to shrink tumors in patients with ovarian, primary peritoneal, and fallopian tube cancers that has spread from where it first started (primary site) to other places in the body (metastatic). PLX038 may stop the growth ...
What is the current status of trial NCT05465941?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2022-09-14. Estimated completion is 2031-12-31.
What conditions does trial NCT05465941 study?
This clinical trial studies the following conditions: Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8.
What interventions are being tested in trial NCT05465941?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Pegylated SN-38 Conjugate PLX038 (DRUG).
Who is sponsoring clinical trial NCT05465941?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05465941 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Platinum-Resistant Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
RECRUITING · Phase 2
-
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
RECRUITING · Phase 2
-
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Platinum-Resistant Ovarian Carcinoma
All registered trials for this condition
Platinum-Resistant Fallopian Tube Carcinoma
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.